Telmisartan vs. Valsartan in Patients With Mild to Moderate Hypertension Following a Missed Dose
Completed
Bayer
Phase 4
2001-10-01
The primary objectives are to demonstrate that MICARDIS® (telmisartan) is statistically
superior to Diovan® (valsartan) in reducing diastolic blood pressure (DBP) following a missed
dose at the end of a 6 to 8-week treatment period as measured by the 24-hour ABPM mean and to
demonstrate that MICARDIS® is statistically superior to Diovan® in reducing DBP during the
last 6-hours of the 24-hour dosing interval as measured by ABPM following a dose of active
study medication at the end of a 6 to 8-week treatment period.
Telmisartan vs. Valsartan in Patients With Mild to Moderate Hypertension Following a Missed Dose
Completed
GlaxoSmithKline
Phase 4
2001-10-01
The primary objectives are to demonstrate that MICARDIS® (telmisartan) is statistically
superior to Diovan® (valsartan) in reducing diastolic blood pressure (DBP) following a missed
dose at the end of a 6 to 8-week treatment period as measured by the 24-hour ABPM mean and to
demonstrate that MICARDIS® is statistically superior to Diovan® in reducing DBP during the
last 6-hours of the 24-hour dosing interval as measured by ABPM following a dose of active
study medication at the end of a 6 to 8-week treatment period.
Telmisartan vs. Valsartan in Patients With Mild to Moderate Hypertension Following a Missed Dose
Completed
Boehringer Ingelheim
Phase 4
2001-10-01
The primary objectives are to demonstrate that MICARDIS® (telmisartan) is statistically
superior to Diovan® (valsartan) in reducing diastolic blood pressure (DBP) following a missed
dose at the end of a 6 to 8-week treatment period as measured by the 24-hour ABPM mean and to
demonstrate that MICARDIS® is statistically superior to Diovan® in reducing DBP during the
last 6-hours of the 24-hour dosing interval as measured by ABPM following a dose of active
study medication at the end of a 6 to 8-week treatment period.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
